Phase I study to assess the safety and tolerability of olaparib in combination with bevacizumab in patients with advanced solid tumours

BACKGROUND: Olaparib (AZD2281) is a potent oral poly(ADP-ribose) polymerase inhibitor with anti-tumour activity and acceptable toxicity as monotherapy in patients with BRCA-deficient cancers. The vascular endothelial growth factor receptor inhibitor bevacizumab has been incorporated into standard of...

Descripción completa

Detalles Bibliográficos
Autores principales: Dean, E, Middleton, M R, Pwint, T, Swaisland, H, Carmichael, J, Goodege-Kunwar, P, Ranson, M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2012
Materias:
Clinical Studies
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3273358/
https://www.ncbi.nlm.nih.gov/pubmed/22223088
http://dx.doi.org/10.1038/bjc.2011.555

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3273358/
https://www.ncbi.nlm.nih.gov/pubmed/22223088
http://dx.doi.org/10.1038/bjc.2011.555

Ejemplares similares